PBS Authorities – Changes to ulcerative colitis program

We understand having access to PBS-subsidised medicines can be critical to patient care. That's why Services Australia and the Department of Health and Aged Care are continuing to work together to increase the number of PBS medicines that can be requested and approved using the Online PBS Authorities system (the system). This will include adalimumab, etrasimod, golimumab, infliximab, ozanimod, tofacitinib, upadacitinib, ustekinumab and vedolizumab for the treatment of moderate to severe ulcerative colitis from 1 April 2025.

These changes will make it easier for you to request authority approval for these medicines from Services Australia. You will no longer need to submit written authority applications, details of the proposed prescriptions and test results for certain medicines and treatment phases. Instead, you will be able to use the system to apply for authority approval and provide evidence digitally.

Summary of changes from 1 April 2025

adalimumab; etrasimod; golimumab; infliximab; ozanimod; tofacitinib; upadacitinib; ustekinumab; vedolizumab online / Written: Initial, grandfather (etrasimod only), recommencement & change treatments When submitted online, the app assessment by a Services Aust known as a Full (Delayer directly to your Health Profess (HPOS) mail Online / Telephone: Continuing & balance of supply treatments Authorities system of When submitted online, the app assessment by a Services Aust known as a Full (Delayer directly to your Health Profess (HPOS) mail No change to continuing or treatment Authority applications can be not the Online PBS Authorities system of the app assessment by a Services Aust known as a Full (Delayer directly to your Health Profess (HPOS) mail		Medicine	Authority Level		Details of Chang	ges	
tofacitinib; upadacitinib; ustekinumab; vedolizumab Online / Telephone: Continuing & balance of supply treatments Authority applications can be not the Online PBS Authorities sy		etrasimod; golimumab;	Initial, grandfather (etrasimod only), recommencement & change treatments	When subn assessme kno When asse	Authority applications can be made using the Online PBS Authorities system or in writing. When submitted online, the application may still require assessment by a Services Australia operator (process known as a Full (Delayed) Assessment). When assessed you will receive an outcome notification directly to your Health Professional Online Service (HPOS) mailbox.		
		tofacitinib; upadacitinib; ustekinumab; Online / T Continuing 8 supply tre	Continuing & balance of	Authority a	No change to continuing or balance of supply treatments. Authority applications can be made in real-time using the Online PBS Authorities system or by telephone.		
Subsequent continuing treatments PBS-subsidised biosimilar I medicines are Authority Requ			Subsequent continuing treatments	PBS-si medicine	Authorities for subsequent continuing treatments with PBS-subsidised biosimilar brands of biological medicines are Authority Required (STREAMLINED)		

If you're submitting the authority application form via post or Health Professional Online Service (HPOS) form upload facility, you'll still need to submit the authority application form and details of the proposed prescriptions.

Please note, the authority application forms that are updated as part of PBS listings changes in April and May 2025 will have the title fields in the prescriber and patient details removed. All remaining forms will be updated on 1 June 2025.

For more information about the **Online PBS Authorities system** visit **www.servicesaustralia.gov.au/hppbsauthorities**

Services Australia has a broad range of educational resources on the **Health Professional Education Resources** website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html

If you require additional assistance or have any queries, please email authority.comms.change@servicesaustralia.gov.au.